SX

China SXT Pharmaceuticals IncNASDAQ SXTC Stock Report

Last reporting period 31 Mar, 2023

Updated 26 Nov, 2024

Last price

Market cap $B

0.002

Micro

Exchange

XNAS - Nasdaq

SXTC Stock Analysis

SX

Uncovered

China SXT Pharmaceuticals Inc is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

-36/100

Low score

Market cap $B

0.002

Dividend yield

Shares outstanding

5.239 B

China Sxt Pharmaceuticals, Inc. is a holding company, which engages in the research, development, manufacture, marketing, and sales of traditional Chinese medicine pieces (TCMP). The company is headquartered in Taizhou, Jiangsu and currently employs 88 full-time employees. The company went IPO on 2019-01-04. The firm develops, manufactures and sells three types of TCMP products: advanced TCMP, fine TCMP and regular TCMP, and TCM Homologous Supplements (TCMHS) products. The firm sells its TCMP products under three brand names such as Suxuangtang, Hui Chun Tang and Tong Ren Tang. Most of its products are sold on a prescription basis across China.

View Section: Eyestock Rating